ORIGINAL RESEARCH article

Front. Allergy

Sec. Rhinology

Volume 6 - 2025 | doi: 10.3389/falgy.2025.1573764

Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio Region, Italy

Provisionally accepted
Francesca AnastasiFrancesca Anastasi1,2*Cristiano Di NotaCristiano Di Nota3Silvia SessiSilvia Sessi3Andrea MarzettiAndrea Marzetti3Anna SambitoAnna Sambito4Marco Della CasaMarco Della Casa4Sofia PizzolanteSofia Pizzolante5Giorgio BandieraGiorgio Bandiera5
  • 1UOC Otorinolaringoiatria, Ospedale San Giovanni Evangelista, Tivoli, Italy
  • 2Departmental Faculty of Medicine, UniCamillus, Saint Camillus International University of Health and Medical Sciences, Rome, Lazio, Italy
  • 3UOC Otorinolaringoiatria, Fabrizio Spaziani Hospital, Frosinone, Lazio, Italy
  • 4UOC Otorinolaringoiatria, Ospedale di Belcolle, Viterbo, Lazio, Italy
  • 5Uoc Otorinolaringoiatria, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Lazio, Italy

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease. Its severe uncontrolled form may share, with asthma and atopic dermatitis, the pathophysiological mechanism of T helper 2 inflammation, characterized by tissue eosinophilia and high local IgE levels. Comorbidities and the severity of symptoms result in a poor quality of life. CRSwNP is difficult to treat both medically and surgically. Systemic corticosteroids are widely used to manage signs and symptoms of this disease. However, prolonged use of systemic corticosteroids is associated with numerous side effects that limit their long-term use. Alternative therapy with new biologic drugs allows good control of the signs and symptoms of CRSwNP, without the side effects of systemic corticosteroids. Through an interview proposed to patients affected by CRSwNP, the use of systemic corticosteroids, their dosage and the methods of administration were analyzed in the period preceding the start of therapy with biological drugs and the real impact of biological therapy on corticosteroid use.

Keywords: CRSwNP, Th2 inflammation, Systemic corticosteroid, Pharmaco economic, Biological theraphy, Astma, IL-5 antibody, anti-IL4

Received: 09 Feb 2025; Accepted: 05 May 2025.

Copyright: © 2025 Anastasi, Di Nota, Sessi, Marzetti, Sambito, Della Casa, Pizzolante and Bandiera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Francesca Anastasi, UOC Otorinolaringoiatria, Ospedale San Giovanni Evangelista, Tivoli, Italy

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material